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Abstract 
Background. Hepato-renal syndrome (HRS) is a func-
tional form of renal failure that occurs in patients with 
end-stage liver disease. Previously considered fatal 
without liver transplantation, treatment with vasocon-
strictors and albumin has been demonstrated to 
improve renal function in patients with type I HRS. 
Liver transplantation is still considered the definitive 
treatment for H RS. However. the renal recovery rate 
and those factors that predict recovery post orthotopic 
liver transplantation have not been determined. 
Methods. We reviewed the hospital course of 
28 patients who met the International Ascites Club 
criteria for type I HRS and who underwent orthotopic 
liver transplant. The patients' demographic and 
pre- and post-operative laboratory data were recorded; 
patients were followed for 4 months post-
transplantation or until death. 
Results. The MELD score of the patients was 30 ± 6. 
The mean duration of HRS prior to liver transplanta-
tion was 37 ± 27 days. HRS resolved in 16 patients 
(58°1,,). The mean time to resolution of HRS was 
21 ±27 days. with a range of4-11O days. Eight (50%) 
patients in whom the HRS resolved were undergoing 
pre-transplantation dialysis. The age of the recipients 
(49 ± 10 vs 56 ± 12; P = 0.05). the total bilirubin level 
on post-operative day 7 (6.0±4.3 vs 10.1 ±5.9mg/dl: 
P = 0.04). alcoholic liver disease and the requirement 
for post-transplant dialysis were predictors of 
resolution of HRS by univariate analysis. Only 
alcoholic liver disease and post-transplant dialysis 
were independent (negative) predictors of resolution 
of H RS. Seven of the 12 (58%) patients who developed 
chronic renal insufficiency remained dialysis depen-
dent. The pre-operative serum creatinine was non-
significantly higher in the non-resolvers who remained 
dialysis dependent compared to those who did not 
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require long-term dialysis (3.0 ± 1.0 vs 2.3 ± 0.4 mg/dl; 
P = 0.1) Four patients died; in three of these patients 
the HRS had resolved prior to their death. 
Conclusion. HRS is not always cured by orthotopic 
liver transplant. Pre-transplantation dialysis or a long 
waiting period should not preclude transplantation 
in patients with HRS. HRS may not resolve in patients 
with alcoholic liver disease. We were unable to 
accurately define that group of patients with HRS 
who required long-term dialysis and could theoretically 
benefit from combined liver-kidney transplantation. 
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Renal failure is a common complication in patients 
with end-stage liver disease [I]. Pre-transplant renal 
dysfunction predicts a poorer outcome following liver 
transplantation [2]. In some cases, renal failure results 
from well-defined insults such as volume depletion. 
nephrotoxic drugs, sepsis or shock. However, in other 
cases renal failure in patients with cirrhosis occurs 
in the absence of well-defined insults and with normal 
renal histology. This disorder is known as the hepa-
torenal syndrome (HRS) [3]. HRS accounts for 
approximately 8°!., of cases of renal failure in patients 
with cirrhosis [3]. Gines and colleagues followed 234 
non-azotemic patients with cirrhosis and ascites for 
5 years; in this study 39% of the patients developed 
HRS [4]. The pathophysiological hallmark of HRS is 
vasoconstriction of the renal circulation. The mecha-
nism of the vasoconstriction is incompletely under-
stood; it may be multifactorial, involving disturbances 
in the circulatory function and activity of the systemic 
and renal vasoactive mechanisms [5,6]. In 1996. the 
International Ascites Club (lAC) established major 
and minor diagnostic criteria for the diagnosis of HRS 
[7]. HRS was further classified as type I and type 2 
according to the rate of decline of renal function [3,7,8] . 
Type 1 was arbitrarily defined as a 100% increase in 
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serum creatinine reaching a value of greater than 
1.5 mg!dl in less than 2 weeks [3,7,8]. Patients who had 
a slower decline in renal function were deemed to have 
type 2 HRS. 
Patients with type 1 HRS have a very poor prognosis 
compared to patients with type 2 HRS [9). The median 
survival time for type 1 HRS has been reported to be 
14 days [3,4,10,11]. The only effective medical therapy 
currently available for the management of HRS is 
the administration of vasoconstrictors together with 
volume expansion with a colloid (usually albumin). 
Volume expansion with colloids and vasopressin 
analogues (ornipressin and terlipressin), norepineph-
rine and somatostatin have been used with variable 
success [12-15]. 
Liver transplantation is considered the treatment 
of choice for patients with cirrhosis and type I HRS 
because it 'allows for both the liver disease and asso-
ciated renal failure to be cured'. Surprisingly, while 
liver transplantation is considered the treatment of 
choice for patients with type I HRS, the percentage of 
patients whose renal function recovers, the time course 
of renal recovery and those factors which predict 
renal recovery have not been studied. These factors 
could influence decisions regarding the pre-operative 
management and timing of transplantation as well as 
the role of combined liver-kidney transplantation [16). 
The purpose of this study was therefore to follow 
renal function post-orthotopic liver transplantation 
in patients with type I HRS and to determine those 
factors predictive of renal recovery. 
Methods 
This study was conducted in the 28 bed Liver Transplant rcu 
(L TICU) in Montefiore Hospital, University of Pittsburgh, 
Pittsburgh. PA. USA. Permission to perform this study was 
obtained from the University of Pittsburgh Institutional 
Review Board. The University of Pittsburgh Medical Center 
has a comprehensive electronic medical record system whieh 
archives patient clinical and laboratory data in a number of 
separate database systems. In addition, the L TICU has a 
separate database whieh records clinical and laboratorv data 
on all patients admitted to the L TICU. Patients admitted to 
the L TICU betwecn Junc 2001 and June 2004 who met the 
lAC criteria for the diagnosis of type I HRS and who 
underwent orthotopic liver transplantation were identified [7]. 
These criteria included: (i) a 100% increase in serum 
creatinine reaching a value of greater than 1.5 mg/dl in less 
than 2 weeks, (ii) absence of shock. ongoing bacterial 
infection, fluid losses, or concurrent treatment with nephro-
toxic drugs, (iii) no sustained improvement in renal function 
with diuretic withdrawal and volume expansion, (iv) protein-
uria of <500 mg/day and (v) no ultrasonographic evidence of 
obstructive uropathy or parenchymal disease. All patients 
with possible HRS were evaluated by a consultant nephrol-
ogist with expertise in the management of patients with 
liver disease. 
Using an honest broker system, a de-identified data file 
was constructed. An honest broker system uses a third party 
(KG) not involved in the study to extract. collate and 
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de-identify data files. The retrieved data included the duration 
of the HRS from the time the patients met the diagnostic 
criteria to the time of transplantation (in days), the need for 
pre-operative renal replacement therapy. history of diabetes 
mellitus and hypertension, the cause of liver failure, pre-
operative laboratory data including liver function tests, 
blood urea nitrogen, serum creatinine and operative details 
(age of donor. cold ischaemic time, warm ischaemic time, 
number of red blood cells transfused during the procedure). 
The model for end-stage liver disease (MELD) equation 
was used to calculate pre-transplant disease severity 
as follows: [0.957 x loge (creatinine mg/dl) + 0.378 x 
logc(bilirubin mg/dl) and 1.12 x loge (INR)+ 0.643] x 10 [17]. 
The minimal values were set at 1.0 for calculation purposes. 
The maximal serum creatinine considered within the MELD 
score equation is 4.0 mg/dl. Post-operative data recorded 
included the need for and duration of renal replacement 
therapy, and daily serum creatinine and total bilirubin. In 
patients receiving haemodialysis, the immediate pre-dialysis 
creatinine level was used. HRS was considered to have 
resolved in patients who remained dialysis free with a serum 
creatinine of less than 1.5 mg/dl. All episodes of post-
operative sepsis were recorded; the Society of Critical Care 
Medicine/ American College of Chest Physicians criteria for 
sepsis were used [18]. Patients were followed for 4 months 
post-transplant or until death. 
During the study period, patients undergoing liver trans-
plantation (cadaveric, living related and non-heart beating 
donors) were treated with a steroid sparing regimen of immu-
nosuppression. Patients received Campath (Alemtuzumab/ 
anti-CD 52 monoclonal antibody. Berlix Laboratories. 
Richmond CAl or thymoglobulin. Post-operative immuno-
suppression included oral tacrolimus which was delayed until 
post-operative day 2 or 3 in patients with HRS, with the 
dosage being adjusted to obtain a whole blood trough level of 
between 5- 10 J,lg/ml. The tacrolimus level was very carefully 
monitored to ensure a trough level of::: 10 J,lgjdl in all patients 
until the HRS resolved. No patients received intravenous 
tacrolimus. 
Statistical analysis 
Summary statistics were compiled to allow a description of 
the patient population. Statistical analysis was done using 
NCSS 2004 (Kaysville. UT). Chi-squared analysis was used to 
compare categorical data. Continuous data were compared 
using Student's (-test. The Mann~thitney U-test was used 
for data that failed tests of normality. Logistic regression 
analysis with forward variable selection was performed to 
determine those variables independently predictive of renal 
recovery. In the multivariate analysis, alcoholic liver disease 
was compared with non-alcoholic, liver disease as binary 
variables. Unless otherwise stated, all data are expressed as 
mean ± SD, with statistical significance declared for prob-
ability values of 0.05 or less. 
Results 
During the period under study, 28 patients with type I 
HRS underwent orthotopic liver transplantation. The 
mean MELD score of the cohort was 30 ± 6; their mean 
age was 51 ± 9 years and 19 (68 %) were male. The mean 
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Table 1. Clinical and demographic characteristics of the patients 
with hepato-rcnal syndrome (HRS) grouped by post-transplant 
renal recovery 
H RS resolved Persistent renal 
11= 16 dysfunction 11= 12 
Age (years) 49± 10 56±12* 
Cause 01" liver disease 
alcohol 3 (Ig%) 8 (67%)** 
hepatitis C 6 (37%) 3 (25%) 
History of diahetes mellitus 5 (31%) 4 (33%) 
History of hypertension 1(6%) 4 (33%) 
Duration of HRS prior 38 ± 31 36±22 
to TIP (days) 
Pre TiP albumin (gidl) 2.9±0.8 2.8 ± 0.6 
Pre TIP creatinine (mg\lI) 3.1 ±2.0 2.U 0.9 
Pre TIP INR 1.8 ± 0.5 2.0 ± 1.0 
Pre T;P bilirubin (mgjdl) 13.3 ± 15.2 16.0± 18.1 
Day 7 hili rubin (mgjdi) 6.0",4.3 10.1 ± 5.9*** 
Pre MELD Score 31..:: '} 29 ± 8 
Cold ischemia time (hours) 658 ± 296 671±227 
Warm ischemia time (minutes) 30±'} 34±8 
Age donor (years) 36± 15 49±21 
Intraoperative PRBC 14±8 21 ±20 
Pre TIP dialysis 8 (50%) ) (42%) 
Post TIP dialysis 7 (43%) 11(91%)' 
Post TIP sepsis 5 (31 'Yo) 4 (33%) 
LOS post TjP 34±29 47 ± 33 
H RS = hepato-renal syndrome: TIP = transplant: LOS = length of 
hospital stay: pRBC = packed red blood cells. 
*P=O.O): **P=O.02: ***P=0.04. 
duration of HRS prior to liver transplantation was 
37±27 days. HRS resolved in 16 patients (58%). The 
clinical characteristics of the patients in whom HRS 
resolved compared to those who progressed to chronic 
renal insufficiency are listed in Table I. The age of the 
recipients (49± 10 liS 56± 12; P=0.05), the total 
bilirubin level on post-operative day 7 (6.0 ± 4.3 \'S 
10.1 ±5.9mg/dl; P=0.04), alcoholic liver disease and 
the requirement for post-transplant dialysis were 
predictors of resolution of HRS by univariate analysis. 
The age of the donor (36 ± 15 vs 49 ± 21; P = 0.07) and 
the number of units of red cells transfused (l4±8 vs 
21 ± 20; P = 0.18) tended to be lower in those patients 
in whom HRS resolved. Only alcoholic liver disease 
and post-transplant dialysis were independent (nega-
tive) predictors of resolution of HRS. The duration of 
the HRS prior to transplantation was 38 ± 31days 
(range 10-11 S) in those in whom HRS resolved and 
36 ± 22 days (range 13--82) in those who progressed to 
chronic renal insufficiency. The mean time to resolution 
of H RS was 21 ± 27 days, with a range of 4---110 days. 
Only two patients demonstrated a rapid improvement 
in renal function with a dramatic increase in urine 
output post-transplant. The time to resolution of HRS 
was longer in those patients receiving pre-transplant 
dialysis: this was, however, not statistically significant 
(34 ± 361'5 12 ± 12 days; P = 0.1). Seven of the 12 (58%) 
patients who developed chronic renal insufficiency 
remained dialysis dependent. The pre-operative serum 
creatinine was non-significantly higher in the non-
resolvers who remained dialysis dependent compared 
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to those who did not require long-term dialysis 
(3.0± l.Omg/dl V5 2.3±0.4mg/dl; P=O.I); the only 
variable which predicted long-term dialysis in the non-
responders was the serum creatinine on post-operative 
day 7 (3.4 ± 0.9 Ilg/dl vs 1.6 ± 0.2 Ilg/dl; P = 0.002). 
Four patients died; in three of these patients the 
HRS had resolved prior to their death. All four of 
these patients required both pre-transplant and post-
transplant dialysis. The mean age of the patients who 
died was 60 ± 5 years compared to 50 ± 9 years in the 
survivors (P = 0.04). 
Discussion 
A review of the literature would suggest that renal 
function improves in most patients with HRS post-
orthotopic liver transplantation [1,3,6,8,19,20]. This 
belief is based on limited data. The main finding of 
our study is that type I HRS resolved in only 58'Yo 
of patients post-transplantation. It could be argued 
that the "low' resolution rate may be due to the fact that 
tacrolimus was used for immunosuppression, and 
that patients with HRS may be more susceptible to 
the nephrotoxicity of this agent. We think this to be 
unlikely, as initiation of tacrolimus was delayed, the 
blood levels were scrupulously monitored to limit the 
risk of nephrotoxicity and no patients received the drug 
intravenously. The requirement for pre-operative dialy-
sis and a long waiting period prior to transplantation 
did not preclude renal recovery. It is generally believed 
that renal function improves immediately following 
transplantation; this pattern was observed in only 
two patients. The mean time to resolution of HRS was 
21 ± 27 days, with a range of 4---110 days. While the 
reported median survival of patients with type I HRS is 
between 14-21 days [3,4,15], we have demonstrated 
that with aggressive medical management. patients 
can be supported for a prolonged time (up to 118 days) 
prior to successful transplantation. This experience is 
similar to that of Capling and Bastani, who reported a 
mean survival time of 236 days of four patients with 
type I HRS who underwent long-term haemodialysis [21]. 
Alcoholic liver disease independently predicted the 
failure of HRS to resolve after transplantation. The 
explanation for this observation is not entirely clear. 
Watt and colleagues reported that patients with 
alcohol-induced liver failure more often had HRS 
than did patients with other forms of liver failure (OR 
45. L CI 13.3-153.5, P=O.OOOOI) [9]. Increased levels of 
tumour necrosis factor-o: (TNF-o:) are found in patients 
with alcoholic liver disease [22,23]. TNF-o: has been 
implicated as a cause of renal failure in patients with 
sepsis [24]. In addition, chronic alcohol abuse may 
increase the risk of renal failure by reducing prosta-
glandin synthesis [25,26], and by damaging the proxi-
mal convoluted tubule [27,28]. Further studies are 
required to confirm this observation. 
Combined liver-kidney transplantation has been 
performed in patients with both hepatic and renal 
failure [29,30]. Data from the United Network for 
Hepato-renal syndrome 
Organ Sharing (UNOS) indicate that 12% of the 
combined liver-kidney transplants performed in the 
US (523 cases from 1988 to 1996) were in patients 
with HRS [31]. The 2- and 5-year overall survival rates 
for non-hepatorenal patients who received combined 
liver kidney transplant were 79.8% and 69.2%, respec-
tively, whereas HRS patients who received only liver 
transplant had 2- and 5-year survival rates of 73.8% 
and 67.1°A), respectively (NS) [31]. In our study, we 
were unable to accurately define that group of patients 
who remained dialysis dependent post-transplant and 
would have potentially benefitted from combined liver-
kidney transplant. However, the non-resolvers received 
organs from donors who tended to be older. they 
required more intra-operative blood transfusions and 
had slower hepatic recovery (higher bilirubin on day 7). 
This suggests that 'marginal' liver should not be used 
in patients with HRS. 
A number of studies have evaluated renal function 
in patients undergoing orthotopic liver transplant. 
Gonwa 1'1 al. reviewed the post-operative course of 
renal function in 294 patients undergoing orthotopic 
liver transplant [19]. In this study, all patients received 
cyclosporin as part of the immunosuppressive protocol. 
H RS was defined by an increasing serum creatinine 
and a fractional sodium excretion (FeNa) of <0.1 % in 
patients with end-stage liver disease. This study did 
not use the lAC criteria for HRS and did not 
distinguish between type 1 and type 2 HRS [3,7,8]. 
Thirty-one (10.5%) patients were considered to have 
HRS. In the non-HRS patients, glomerular filtration 
rate (GFR) declined from 97.1 ml/min at baseline to 
56 ml/min at 6 weeks post-operation. 62 ml/min at 
I year and 58.3 ml/min at 2 years. In the patients with 
HRS. GFR increased from 19.9ml/min at baseline to 
32.5 mllmin at 6 weeks, 45.9 ml/min at 1 year and 
37.9ml/min at 2 years. Ten percent of HRS patients 
developed ESRD post-transplant compared to 0.8% of 
non- HRS patients (P < 0.005). The actuarial 1 and 2 
year survival rates were similar in the non-HRS and 
HRS groups. In a follow-up study of 569 patients 
undergoing liver transplantation, these investigators 
reported a decreased actuarial 5-year survival in 
patients with HRS compared to patients without 
HRS (60 \'.1' 68%, P<0.03) [I]. 
Restuccia and colleagues compared the outcome of 
nine patients with HRS (three with type I HRS) who 
had been treated with vasopressin analogues before 
transplantation with a contemporary control group 
of patients (/I = 27) without HRS [32]. The 3 year 
survival probability was similar between the two groups 
( I 00% H RS I'S 83 % control) and there were no 
significant differences between the two groups with 
respect to the incidence of renal impairment after 
transplantation. severe infections, acute rejection and 
LOS. Cassinello and coworkers studied the effect of 
orthotopic liver transplantation on vasoactive systems 
and renal function in 22 patients with cirrhosis [6]. 
In this study. there was a significant increase in the 
creatinine clearance and a significant fall in serum 
norepinephrine, plasma renin activity and endothelin-l 
4g1 
levels in both patients with and without HRS post-
transplan ta tion. 
Although our study is limited by its retrospective 
design and small sample size, we demonstrated 
that at our centre, type 1 HRS resolved in 58% of 
patients post-orthotopic liver transplant. The mean 
time to resolution of renal failure was 21 days. Pre-
transplantation dialysis or a long waiting period 
should not preclude transplantation in patients with 
HRS. HRS may not resolve in patients with alcoholic 
liver disease. HRS should not be considered an 
indication for combined liver-kidney transplantation. 
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